142 related articles for article (PubMed ID: 6362674)
1. Relative mutagenicity and teratogenicity of cyclophosphamide and two of its structural analogs.
Hales BF
Biochem Pharmacol; 1983 Dec; 32(24):3791-5. PubMed ID: 6362674
[TBL] [Abstract][Full Text] [Related]
2. Mutagenic, teratogenic and pharmacokinetic properties of cyclophosphamide and some of its deuterated derivatives.
Nau H; Spielmann H; Lo Turco Mortler CM; Winckler K; Riedel L; Obe G
Mutat Res; 1982 Aug; 95(2-3):105-18. PubMed ID: 6750378
[TBL] [Abstract][Full Text] [Related]
3. Modification of the mutagenicity and teratogenicity of cyclophosphamide in rats with inducers of the cytochromes P-450.
Hales BF
Teratology; 1981 Aug; 24(1):1-11. PubMed ID: 7029774
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramide mustard, and acrolein.
Hales BF
Cancer Res; 1982 Aug; 42(8):3016-21. PubMed ID: 7046914
[No Abstract] [Full Text] [Related]
5. Teratogenicity and embryolethality of acrolein and structurally related compounds in rats.
Slott VL; Hales BF
Teratology; 1985 Aug; 32(1):65-72. PubMed ID: 4035593
[TBL] [Abstract][Full Text] [Related]
6. Role of the 4-hydroxy intermediate in the in vitro embryotoxicity of cyclophosphamide and dechlorocyclophosphamide.
Slott VL; Hales BF
Toxicol Appl Pharmacol; 1988 Feb; 92(2):170-8. PubMed ID: 3341031
[TBL] [Abstract][Full Text] [Related]
7. Licorice extract increases cyclophosphamide teratogenicity by upregulating the expression of cytochrome P-450 2B mRNA.
Park D; Yang YH; Choi EK; Yang G; Bae DK; Lee SH; Kim TK; Kyung J; Kim D; Choi KC; Kim YB
Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):553-9. PubMed ID: 21818843
[TBL] [Abstract][Full Text] [Related]
8. Role of acrolein in cyclophosphamide teratogenicity in rat embryos in vitro.
Mirkes PE; Greenaway JC; Rogers JG; Brundrett RB
Toxicol Appl Pharmacol; 1984 Feb; 72(2):281-91. PubMed ID: 6546458
[TBL] [Abstract][Full Text] [Related]
9. Preventive effect of piperonyl butoxide on cyclophosphamide-induced teratogenesis in rats.
Park D; Kim S; Kang H; Oh J; Jang JY; Shin S; Kim TK; Choi YJ; Lee SH; Kim KY; Joo SS; Kim YB
Birth Defects Res B Dev Reprod Toxicol; 2009 Oct; 86(5):402-8. PubMed ID: 19851987
[TBL] [Abstract][Full Text] [Related]
10. Transplacental teratogenesis and mutagenesis in mouse fetuses treated with cyclophosphamide.
Porter AJ; Singh SM
Teratog Carcinog Mutagen; 1988; 8(4):191-203. PubMed ID: 2906177
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide: interstrain differences in the production of mutagenic metabolites by S9-fractions from liver and kidney in different mutagenicity test systems in vitro and in the teratogenic response in vivo between CBA and C 57 BL mice.
Winckler K; Obe G; Madle S; Kocher-Becker U; Kocher W; Nau H
Teratog Carcinog Mutagen; 1987; 7(4):399-409. PubMed ID: 2888218
[TBL] [Abstract][Full Text] [Related]
12. Green tea extract increases cyclophosphamide-induced teratogenesis by modulating the expression of cytochrome P-450 mRNA.
Park D; Jeon JH; Shin S; Joo SS; Kang DH; Moon SH; Jang MJ; Cho YM; Kim JW; Ji HJ; Ahn B; Oh KW; Kim YB
Reprod Toxicol; 2009 Jan; 27(1):79-84. PubMed ID: 19103281
[TBL] [Abstract][Full Text] [Related]
13. Sodium 2-mercaptoethane sulfonate protection against cyclophosphamide-induced teratogenicity in rats.
Slott VL; Hales BF
Toxicol Appl Pharmacol; 1986 Jan; 82(1):80-6. PubMed ID: 3080822
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the control of mutagenic metabolites derived from cyclophosphamide and ifosfamide by stimulation of protein kinase A.
Oesch-Bartlomowicz B; Vogel S; Arens HJ; Oesch F
Mutat Res; 1990 Oct; 232(2):305-12. PubMed ID: 2170835
[TBL] [Abstract][Full Text] [Related]
15. Mutagenicity of dibromodulcitol (DBD), an alkylating anticancer drug) and its mono- and bifunctional conversion products studied by the Salmonella/microsome assay.
Tóth K; Sugár J; Somfai-Relle S; Hedegüs L
Carcinogenesis; 1982; 3(3):333-6. PubMed ID: 7044598
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of the embryotoxicity of acrolein, but not phosphoramide mustard, by glutathione depletion in rat embryos in vitro.
Slott VL; Hales BF
Biochem Pharmacol; 1987 Jun; 36(12):2019-25. PubMed ID: 3593406
[TBL] [Abstract][Full Text] [Related]
17. The embryolethality and teratogenicity of acrolein in cultured rat embryos.
Slott VL; Hales BF
Teratology; 1986 Oct; 34(2):155-63. PubMed ID: 3775668
[TBL] [Abstract][Full Text] [Related]
18. Aspects of the teratology of cyclophosphamide (NSC-26271).
Ashby R; Davis L; Dewhurst BB; Espinal R; Penn RN; Upshall DG
Cancer Treat Rep; 1976 Apr; 60(4):477-82. PubMed ID: 1277224
[TBL] [Abstract][Full Text] [Related]
19. [Study of promutagen biotransformation in the Ames test. III. The role of conjugation with glucuronic acid and sulfate in the modification of mutagenic effect of nitrosomorpholine, diethylnitrosamine and cyclophosphamide].
Loknitskaia NN; Rotenberg IuS; Fonshteĭn LM; Shuliakovskaia TS
Genetika; 1986 Sep; 22(9):2259-64. PubMed ID: 3533722
[TBL] [Abstract][Full Text] [Related]
20. Teratogenicity of cyclophosphamide metabolites: phosphoramide mustard, acrolein, and 4-ketocyclophosphamide in rat embryos cultured in vitro.
Mirkes PE; Fantel AG; Greenaway JC; Shepard TH
Toxicol Appl Pharmacol; 1981 Apr; 58(2):322-30. PubMed ID: 7245204
[No Abstract] [Full Text] [Related]
[Next] [New Search]
